BioSpace News Archive

Lineage Cell Therapeutics, Inc. today reported financial and operating results for the fourth quarter and full year ended December 31, 2022 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results.

Stealth BioTherapeutics Inc. today announced that the company will present an overview of the elamipretide clinical development program in Barth syndrome at the 2023 American College of Medical Genetics Meeting, to be held March 14-18, 2023 in Salt Lake City, Utah.

At this year’s American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, held March 7 to 11 in Las Vegas, Hospital for Special Surgery (HSS) presented new research on a variety of topics in orthopedic surgery, including studies related to minimally invasive surgery, racial disparities, and opioid alternatives for pain management in spine care.

The 2023 American Academy of Dermatology Annual Meeting will take place March 17-21 at the Ernest N. Morial Convention Center in New Orleans.

ALX Oncology Holdings Inc. reported financial results for the fourth quarter and year ended December 31, 2022 and provided clinical development and operational highlights.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported fourth quarter and full year 2022 financial results.

Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2022.

aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2022 results and provided a corporate update.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter 2022 financial results.

Sight Sciences, Inc. announced the United States launch of the Ergo-Series of the OMNI® Surgical System, a technology that facilitates surgeons’ ability to perform minimally invasive, implant-free glaucoma procedures in adults with primary open-angle glaucoma.